Table 2. MSH2 Expression, Progression-Free Survival, and Overall Survival in Patients from the Bio-IFCT 0002 Trial.

Outcome		MSH2 < Q2 n =167	MSH2 ≥ Q2 n =189	p	BRCA1 < Q2 n =92	BRCA1 ≥ Q2 n =129	p	MSH2 < Q2 + BRCA1 ≥ Q2 n =67	Other n = 137	p
PFS	Number of events	97	120		92	69		32	86
	Median (month)	36.1 [24.1-61.1]	35.4 [23.2-46.4]		16.2 [13.3-36.0]	54.2 [39.8-ND]		ND	32.5 [16.0-49.1]
	HR (95% CI)	0.88 [0.67-1.14]	1	0.33	1.44 [1.01-2.04]	1	0.04	0.62 [0.42-0.94]	1	0.02
	Adj. HR‡ (95% CI)	-	-	-	-	-	-	0.63 [0.42-0.95]	1	0.03
OS	Number of events	66	102		49	51		21	70
	Median (month)	ND	60.5 [44.6–77.8]		47.1 [28.1-ND]	90.6 [73.5-ND]		ND	66.5 [42.3-ND]
	HR (95% CI)	0.65 [0.48-0.89]	1	0.007	1.58 [1.07-2.34]	1	0.02	0.50 [0.31-0.82]	1	0.006
	Adj. HR‡ (95% CI)	0.66 [0.48-0.90]	1	0.008	1.58 [1.07- 2.34]	1	0.02	0.51 [0.31-0.83]	1	0.006

‡ HR was adjusted according to histology, stage, and gender for OS; HR was adjusted according to histology and stage for PFS